If you've searched for help with chemobrain — the brain fog, word-finding difficulty, slower thinking, and memory lapses that affect many patients on chemotherapy — you've probably encountered a spectrum of advice.
At one end: careful, hedged summaries of limited studies, acknowledging that the evidence is incomplete and that no treatment is approved. At the other: supplement recommendations, dietary protocols, and wellness programs offered with a confidence the science doesn't support.
Neither extreme is helpful to a patient trying to function — at work, at home, in relationships — while managing the cognitive effects of cancer treatment.
This piece tries to occupy the honest middle: what interventions have real evidence behind them, what has some evidence but uncertain magnitude, and what is probably not worth your energy.
One caveat first: there are no approved pharmacological treatments for chemotherapy-induced cognitive impairment (CICI). That is not a failure to mention them — it is a fact about where the field currently is. What follows is about what exists now.
What has reasonably good evidence
Exercise
Of all the non-pharmacological interventions studied for chemobrain, aerobic exercise has the most consistent evidence behind it.
Multiple randomized controlled trials have shown that regular aerobic exercise during and after chemotherapy is associated with meaningfully better cognitive outcomes — specifically in attention, processing speed, and memory — compared to usual care. The effect sizes are not enormous, but they are consistent across studies, and the biological rationale is solid: exercise promotes neuroplasticity, increases cerebral blood flow, reduces systemic inflammation, and supports the health of the hippocampus, the brain structure most central to memory formation.
The practical challenge is obvious. Chemotherapy causes fatigue, nausea, and physical depletion. Asking a patient in active treatment to exercise regularly is asking a lot. The evidence does not require marathon training. Studies showing benefit have used moderate-intensity walking programs of 30 minutes three to five times a week. The question to ask is: what is the most activity that is realistic, given how you feel today?
Cognitive rehabilitation
Structured cognitive training — formal exercises designed to practice specific cognitive skills like attention, working memory, and processing speed — has shown benefit in several well-designed trials in cancer survivors.
This doesn't mean brain training apps purchased online. The interventions with the best evidence are delivered by trained neuropsychologists or cognitive rehabilitation specialists, using structured protocols. Access to these programs is uneven, and they are not always covered by insurance, but they are worth asking for — particularly for patients whose cognitive symptoms are significantly affecting their work or daily functioning.
The research suggests that cognitive rehabilitation is most effective when started after active treatment rather than during it, when the brain has more capacity to engage with structured training.
Sleep
The relationship between sleep and cognitive function is so fundamental that it can be understated: sleep is the brain's primary maintenance period. Glial cells clear metabolic waste from the brain during sleep. Memory consolidation happens during sleep. Inflammatory regulation occurs during sleep.
Many patients on chemotherapy have severely disrupted sleep — from pain, nausea, anxiety, steroid medications, and the general physiological upheaval of treatment. The cognitive consequences of this disruption compound the direct effects of the drugs.
Treating sleep aggressively is not a cure for chemobrain, but sleep deprivation reliably worsens every cognitive symptom. Where sleep disruption is present and addressable — whether through behavioral sleep interventions (cognitive behavioral therapy for insomnia, or CBT-I, is the most effective non-pharmacological approach), medication review with the oncologist, or symptom management — improving sleep is almost certainly improving cognitive function too.
Treating depression and anxiety
This one is underemphasized in most chemobrain discussions, probably because it feels too obvious — but it is not obvious to many patients experiencing cognitive symptoms for the first time.
Depression and anxiety are both cognitively impairing on their own. They impair memory encoding, attention, processing speed, and executive function in ways that are indistinguishable, on symptom reports, from the cognitive effects of chemotherapy itself. Many patients going through cancer treatment are experiencing significant depression or anxiety, which is completely understandable and also completely treatable.
If cognitive symptoms are present alongside mood symptoms, treating the mood disorder — whether through therapy, medication, or both — may improve cognitive function substantially. This is not the same as saying chemobrain is "just" depression (it isn't), but the two conditions coexist often enough that failing to treat depression while attributing all cognitive symptoms to chemotherapy is a clinical error.
What has some evidence but uncertain magnitude
Omega-3 fatty acids
Several small studies have suggested that omega-3 supplementation — particularly DHA — during chemotherapy may offer some protection against cognitive decline. The biological rationale is reasonable: omega-3s are anti-inflammatory and important for neuronal membrane health.
The evidence is not yet strong enough to make a firm recommendation, and the studies are heterogeneous in design, dose, and population. That said, omega-3 supplementation is generally safe, has other cardiovascular benefits, and has a plausible mechanism. It is not unreasonable for a patient to discuss with their oncologist.
Important caveat: some omega-3 formulations can affect bleeding time and interact with certain chemotherapy regimens. Do not add any supplement during active treatment without checking with your oncologist first. This applies to omega-3s and to everything else.
Mindfulness-based stress reduction (MBSR)
Several trials have tested mindfulness-based programs — typically eight-week structured courses in meditation and mindfulness practices — in cancer survivors with cognitive symptoms. Results have been modestly positive, primarily on subjective cognitive complaints and quality of life.
The evidence for objective neuropsychological improvement (as measured by standardized tests rather than patient reports) is weaker and more inconsistent. MBSR appears to help patients feel less impaired by their cognitive symptoms, which is genuinely meaningful, even if it may not be changing the underlying cognitive function.
For patients who find structured mindfulness practice accessible, it is a low-risk intervention with real quality-of-life upside. It should be pursued for its genuine benefits rather than as a cognitive treatment.
Stimulant medications
Drugs like methylphenidate (Ritalin) and modafinil have been studied in cancer patients with fatigue and cognitive symptoms, primarily as a way to improve attention and alertness. The results have been inconsistent: some trials show modest improvements in attention and processing speed; others show no benefit.
These are prescription medications with real side effect profiles and interactions with cancer treatments. This is emphatically not an area for self-prescribing. If cognitive fatigue is significantly impairing daily function, a conversation with the oncologist about whether a stimulant trial makes sense is reasonable — but only in a carefully supervised medical context.
What probably isn't worth your energy
Most supplement protocols marketed to cancer patients
The supplement industry has not missed the chemobrain population. There are many products — marketed under various wellness framings — claiming to support cognitive function during and after cancer treatment.
Most of these claims are not supported by clinical evidence in CICI populations. They are sometimes based on in vitro studies, animal models, or studies in healthy populations that don't translate to chemotherapy patients. Some supplements interact with chemotherapy in ways that can reduce treatment efficacy. This is not a small risk.
Until a supplement has been specifically studied in cancer patients and shown to be both safe alongside chemotherapy and effective in reducing cognitive symptoms, the default should be skepticism.
"Detox" protocols
The logic that chemotherapy toxins linger in the body and cause ongoing symptoms — and that "detoxing" them will resolve cognitive impairment — is not supported by the biology. The liver and kidneys clear chemotherapy agents from the body through normal metabolic processes. There is no credible evidence that special protocols accelerate this or that their absence prolongs cognitive symptoms.
More importantly, some detox products contain compounds that interact with liver enzymes and can affect drug metabolism. In a patient who has recently been on chemotherapy, this is not a theoretical concern.
Doing nothing while waiting for symptoms to resolve
This one is worth naming because it is the default for many patients — particularly those who've been told their symptoms are normal and will pass.
Some chemobrain symptoms do improve over time for some patients, particularly in the first year after treatment ends. But for a meaningful subset — estimates range from 10–35% of affected patients — symptoms persist for years. The evidence base for cognitive rehabilitation suggests that earlier intervention is better, as is earlier identification and treatment of contributing factors like depression, sleep disruption, and anxiety.
Waiting passively is a choice with a cost.
The bigger picture
There is a reason the evidence base for chemobrain interventions is relatively thin: the condition has been insufficiently studied, partly because it has been insufficiently taken seriously. Clinical trials in CICI are difficult and expensive to run. Cognitive endpoints are harder to standardize than tumor response rates. And for a long time, the implicit message from oncology was that cognitive symptoms were a tolerable price for survival.
The research community has moved well past that framing. The survivor population is growing — millions of patients in the U.S. alone are living with some degree of cognitive impairment after cancer treatment. The pressure to develop real treatments is finally building.
At Nulyn Science, we are developing NS-001 as a preventive treatment for CICI — an intervention designed to interrupt the neuroinflammatory cascade before cognitive symptoms develop, administered around the time of chemotherapy. A Phase 2 trial in this indication is planned to begin by the end of 2026.
A real treatment is not here yet. But the field is finally moving, and the goal is not longer-term adaptation to cognitive impairment — it is prevention.